Free Trial
Tada emoji MarketBeat All Access — Now Just $5.00 for 5 Weeks
NASDAQ:IMAB

I-Mab Q2 2025 Earnings Report

I-Mab logo
$4.52 +0.31 (+7.36%)
Closing price 04:00 PM Eastern
Extended Trading
$4.41 -0.11 (-2.41%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

I-Mab EPS Results

Actual EPS
N/A
Consensus EPS
-$0.10
Beat/Miss
N/A
One Year Ago EPS
N/A

I-Mab Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

I-Mab Announcement Details

Quarter
Q2 2025
Date
8/20/2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 20, 2025
Conference Call Time
7:00AM ET

Conference Call Resources

Powered by Quartr

Earnings Documents

I-Mab's Q2 2025 Press ReleasePress Release
(8-K)

I-Mab Earnings Headlines

I-Mab Reports Second Quarter 2025 Financial Results and Provides Business Update
 |  tmcnet.comhttps://www.tmcnet.com/usubmit/2025/08/20/10241702.htm
I-Mab price target raised to $6 from $5 at Needham
 |  msn.comhttps://www.msn.com/en-us/money/topstocks/i-mab-price-target-raised-to-6-from-5-at-needham/ar-AA1KU2w9
Trump’s national nightmare is here
Porter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger the biggest forced rotation of capital since World War II. They reveal why Trump is mobilizing America’s tech giants… and name the two stocks most likely to soar as trillions shift behind the scenes.tc pixel
August 20 at 2:00 AM  |  Porter & Company (Ad)
I-Mab Reports Strong Financials and Clinical Progress in August 2025
 |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/i-mab-reports-strong-financials-and-clinical-progress-in-august-2025/ar-AA1KSBnD
I MAB (ADS) options imply 11.8% move in share price post-earnings
August 19 at 7:44 AM  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/i-mab-ads-options-imply-11-8-move-in-share-price-post-earnings/ar-AA1KKQmS
Everest Medicines announces strategic equity investment in I-Mab
August 1, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/everest-medicines-announces-strategic-equity-investment-in-i-mab/ar-AA1JJNmP
See More I-Mab Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like I-Mab? Sign up for Earnings360's daily newsletter to receive timely earnings updates on I-Mab and other key companies, straight to your email.

About I-Mab

I-Mab (NASDAQ:IMAB), a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland.

View I-Mab Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles